Sodium valproate: an old drug with new roles

Trends in Pharmacological Sciences

Volumn 30, Issue 10, 2009, Pages 509-514

  Nalivaeva, Natalia N ^a,b   Belyaev, Nikolai D ^a   Turner, Anthony J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; HISTONE DEACETYLASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; VALPROIC ACID; VORINOSTAT;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DNA METHYLATION; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HEMOGLOBINOPATHY; HUMAN; HUNTINGTON CHOREA; LEARNING; LOW DRUG DOSE; MEMORY CONSOLIDATION; NEOPLASM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENILE PLAQUE; SPINAL MUSCULAR ATROPHY; THYROID CARCINOMA;

ANIMALS; ANTICONVULSANTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; VALPROIC ACID;

EID: 70349188426     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.07.002     Document Type: Article

References (45)

1. Meunier H., et al. Pharmacodynamic properties of n-dipropylacetic acid. Therapie 18 (1963) 435-438
2. Peterson G.M., and Naunton M. Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30 (2005) 417-421
3. Gerstner T., et al. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin. Pharmacother. 9 (2008) 285-292
4. Godin Y., et al. Effects of n-dipropylacetate, an anticonvulsive compound, on GABA metabolism. J. Neurochem. 16 (1969) 869-873
5. Whittle S.R., and Turner A.J. Effects of the anticonvulsant sodium valproate on γ-aminobutyrate and aldehyde metabolism in ox brain. J. Neurochem. 31 (1978) 1453-1459
6. Large, C.H. et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res. 85, 96-106
7. Zeise M.L., et al. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 544 (1991) 345-348
8. Guidotti A., et al. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci. 30 (2008) 55-60
9. Göttlicher M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
10. Tremolizzo L., et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. USA 99 (2002) 17095-17100
11. Qing H., et al. Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med. 205 (2008) 2781-2789
12. Belyaev N.D., et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 10 (2009) 94-100
13. Akbarian S., and Huang H.S. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol. Psychiatry 65 (2009) 198-203
14. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
15. Rotili D., et al. Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and β-hemoglobinopathies. Curr. Top. Med. Chem. 9 (2009) 272-291
16. Noguchi H., et al. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr. J. 56 (2009) 245-249
17. Hunt C.E., and Turner A.J. Cell biology, regulation and inhibition of β-secretase (BACE-1). FEBS J. 276 (2009) 1845-1859
18. Allinson T.M., et al. ADAMs family members as amyloid precursor protein α-secretases. J. Neurosci. Res. 74 (2003) 342-352
19. Pearson H.A., and Peers C. Physiological roles for amyloid β peptides. J. Physiol. 575 (2006) 5-10
20. Weller R.O., et al. Perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 18 (2008) 253-266
21. Nalivaeva, N.N. et al. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 5, 212-224
22. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
23. Pardossi-Piquard R., et al. Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP. Neuron 46 (2005) 541-554
24. Ryan K.A., and Pimplikar S.W. Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J. Cell Biol. 171 (2005) 327-335
25. Zhang Y.W., et al. Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc. Natl. Acad. Sci. USA 104 (2007) 10613-10618
26. Alves da Costa C., et al. Presenilin-dependent γ-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J. Neurosci. 26 (2006) 6377-6385
27. Vincent B., et al. p53-Dependent transcriptional control of cellular prion by presenilins. J. Neurosci. 29 (2009) 6752-6760
28. Cao X., and Südhof T.C. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293 (2001) 115-120
29. Fischer A., et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 447 (2007) 178-182
30. Guan J.-S., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (2009) 55-60
31. Ricobaraza A., et al. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34 (2009) 1721-1732
32. Lazarov O., et al. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
33. Krämer O.H., et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22 (2003) 3411-3420
34. Thomas E.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. USA 105 (2008) 15564-15569
35. Rai M., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3 (2008) e1958
36. Chen P.S., et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149 (2007) 203-212
37. Wu X., et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacology 11 (2008) 1123-1134
38. Gardian G., et al. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 5 (2008) 235-241
39. Gray S.G., and Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1 (2006) 67-75
40. Shen S., et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 11 (2008) 1024-1034
41. Camelo S., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164 (2005) 10-21
42. Echaniz-Laguna A., et al. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr. Med. Chem. 15 (2008) 1263-1273
43. Langley B., et al. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke 40 (2009) 2899-2905
44. Kazantsev A.G., and Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7 (2008) 854-868
45. Palop J.J., and Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 66 (2009) 435-440